JP2019534889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534889A5 JP2019534889A5 JP2019520110A JP2019520110A JP2019534889A5 JP 2019534889 A5 JP2019534889 A5 JP 2019534889A5 JP 2019520110 A JP2019520110 A JP 2019520110A JP 2019520110 A JP2019520110 A JP 2019520110A JP 2019534889 A5 JP2019534889 A5 JP 2019534889A5
- Authority
- JP
- Japan
- Prior art keywords
- gly
- phe
- antibody
- polymer
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000562 conjugate Substances 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000580 polymer-drug conjugate Substances 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 229960000578 gemtuzumab Drugs 0.000 claims 3
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 claims 2
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229960001743 golimumab Drugs 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- OLQFXOWPTQTLDP-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCO OLQFXOWPTQTLDP-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- MZGMQAMKOBOIDR-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCO MZGMQAMKOBOIDR-UHFFFAOYSA-N 0.000 claims 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims 1
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 claims 1
- SOTXLXCVCZAKFI-FXQIFTODSA-N Ala-Val-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O SOTXLXCVCZAKFI-FXQIFTODSA-N 0.000 claims 1
- DHONNEYAZPNGSG-UBHSHLNASA-N Ala-Val-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DHONNEYAZPNGSG-UBHSHLNASA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 claims 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 claims 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 claims 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 claims 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 claims 1
- IGOYNRWLWHWAQO-JTQLQIEISA-N Gly-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-JTQLQIEISA-N 0.000 claims 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 claims 1
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 claims 1
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 claims 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 claims 1
- BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 claims 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
- 229940126592 Ibritsumomab Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 claims 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 claims 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims 1
- -1 methacrylic nitrile Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000011581 secondary neoplasm Diseases 0.000 claims 1
- 229920006251 semi-telechelic polymer Polymers 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408512P | 2016-10-14 | 2016-10-14 | |
| US62/408,512 | 2016-10-14 | ||
| US201762449209P | 2017-01-23 | 2017-01-23 | |
| US62/449,209 | 2017-01-23 | ||
| PCT/US2017/056515 WO2018071767A1 (en) | 2016-10-14 | 2017-10-13 | Antibody-polymer-drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534889A JP2019534889A (ja) | 2019-12-05 |
| JP2019534889A5 true JP2019534889A5 (https=) | 2020-11-19 |
| JP7390000B2 JP7390000B2 (ja) | 2023-12-01 |
Family
ID=61905991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520110A Active JP7390000B2 (ja) | 2016-10-14 | 2017-10-13 | 抗体－ポリマー－薬物コンジュゲート |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11801307B2 (https=) |
| EP (1) | EP3525808A4 (https=) |
| JP (1) | JP7390000B2 (https=) |
| WO (1) | WO2018071767A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| TR201911542A2 (tr) * | 2019-07-30 | 2021-02-22 | Bogazici Ueniversitesi | Anti̇kor-poli̇mer konjugatlari |
| CZ309828B6 (cs) * | 2019-10-09 | 2023-11-15 | I.T.A.-Intertact S.R.O. | Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113583178B (zh) * | 2020-07-31 | 2023-05-05 | 四川大学华西医院 | 一种支化含糖聚合物基纳米粒子及其的制备方法和用途 |
| CN115607695B (zh) * | 2021-07-15 | 2023-12-05 | 广东精观生物医药科技有限公司 | 一种贝伐珠单抗多模态分子探针的制备方法和应用 |
| EP4496596A2 (en) * | 2022-03-21 | 2025-01-29 | Valitor, Inc. | Method of treating a cancer with a multivalent peptide conjugate |
| CN115025251B (zh) * | 2022-05-18 | 2024-02-09 | 苏州大学附属第一医院 | 自组装psma靶向物、制备方法、组合物及其应用 |
| CN115286669B (zh) * | 2022-07-15 | 2025-03-25 | 北京大学 | 抗体-高分子-药物偶联物的制备方法及应用 |
| WO2026019636A1 (en) * | 2024-07-15 | 2026-01-22 | The Regents Of The University Of California | Use of amiloride and derivatives to treat adverse events due to the use of antibody drug conjugates |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ293787B6 (cs) | 2001-12-20 | 2004-07-14 | Zentiva, A.S. | pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii |
| US7662360B2 (en) * | 2002-07-22 | 2010-02-16 | Psimei Pharmaceuticals Plc | Conjugates of N-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds |
| CZ294996B6 (cs) * | 2003-07-16 | 2005-04-13 | Ústav Makromolekulární Chemie Av Čr | Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů |
| CZ302830B6 (cs) * | 2009-12-15 | 2011-11-30 | Ústav makromolekulární chemie AV CR, v.v.i. | Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru |
| JP5944836B2 (ja) | 2010-03-08 | 2016-07-05 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 高分子薬物送達結合体ならびにその製造および使用方法 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| ES2402614B1 (es) * | 2011-10-24 | 2014-03-18 | Centro De Investigación Principe Felipe | Sintesis controlada de poliglutamatos con baja polidispersidad y arquitecturas versátiles |
| JP6524059B2 (ja) | 2013-03-12 | 2019-06-05 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | アポトーシスを誘導するための組成物及び方法 |
| CN116098433B (zh) | 2016-05-04 | 2024-11-22 | 哈迪·斯坦曼 | 便携式饮料容器 |
| CN106512003B (zh) * | 2016-10-27 | 2019-07-12 | 深圳先进技术研究院 | 一种可注射的肿瘤靶向性热敏前药及其制备方法与应用 |
-
2017
- 2017-10-13 JP JP2019520110A patent/JP7390000B2/ja active Active
- 2017-10-13 WO PCT/US2017/056515 patent/WO2018071767A1/en not_active Ceased
- 2017-10-13 US US16/334,301 patent/US11801307B2/en active Active
- 2017-10-13 EP EP17859454.5A patent/EP3525808A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534889A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| ES2742216T3 (es) | Polímeros que contienen zwitteriones de alto peso molecular | |
| Pan et al. | Backbone degradable multiblock N-(2-hydroxypropyl) methacrylamide copolymer conjugates via reversible addition− fragmentation chain transfer polymerization and thiol− ene coupling reaction | |
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| AR048098A1 (es) | Conjugados de caliqueamicina | |
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| JP2016512832A5 (https=) | ||
| JP2021519076A5 (https=) | ||
| JPWO2020031936A5 (https=) | ||
| SG170730A1 (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP2018537975A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2016531915A5 (https=) | ||
| JP2017537893A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2008546792A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2025183307A5 (https=) | ||
| CN110366430A (zh) | 用于靶向递送试剂的生物相容且亲水的聚合物缀合物 | |
| JP2020534300A5 (https=) | ||
| JP2021503915A5 (https=) |